Citius Oncology, Inc.
CTOR Nasdaq Pharmaceutical Preparations Financials FY2024–FY2025
Last close · Oct 23, 2026
$0.58
17.2%What Citius Oncology, Inc. does
No business description yet.
- Legal name
- CITIUS ONCOLOGY, INC.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 10-K · Dec 23, 2025
- Accession · CIK
- 0001213900-25-125331
0001851484
Revenue and margins
Citius Oncology, Inc. had — of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Citius Oncology, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 7.7%.
Balance sheet
Cash, debt and the ratios that show how comfortably Citius Oncology, Inc. can carry it.
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | $0.0M | $3.9M |
| Interest coverage | — | −107.9x |
| Current ratio | 0.3x | 0.6x |
| Quick ratio | 0.1x | 0.1x |
| Total assets | $84.4M | $101M |
| Total liabilities | $38.2M | $56.1M |
| Shareholders' equity | $46.1M | $44.9M |
| Net debt (− = net cash) | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | ✕ | ✕ |
| Cash from operations is positive | ✓ | ✕ |
| Return on assets rose | — | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | ✓ |
| Share count didn't rise | — | ✕ |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | — |
| F-score | — / 3 | — / 6 |
| Accruals ratio | −25.2% | −20.8% |
| Altman Z'' | −3.58 | −4.22 |
2 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Research and development | $4.9M | $6.4M |
| Operating income | −$20.6M | −$23.5M |
| Interest expense | — | $0.2M |
| Pretax income | −$20.6M | −$23.7M |
| Income tax | $0.6M | $1.1M |
| Net income | −$21.1M | −$24.8M |
| Diluted EPS | −$0.31 | −$0.34 |
| Diluted shares | 0.07B | 0.07B |
| Cash flow | ||
| Cash from operations | $0.1M | −$5.5M |
| Stock-based compensation | $7.5M | $8.3M |
| Balance sheet | ||
| Cash and short-term investments | $0.0M | $3.9M |
| Current assets | $11.0M | $27.5M |
| Current liabilities | $32.7M | $49.5M |
| Inventory | $8.3M | $22.3M |
| Total assets | $84.4M | $101M |
| Total liabilities | $38.2M | $56.1M |
| Shareholders' equity | $46.1M | $44.9M |
| Returns | ||
| Return on capital employed | −39.8% | −45.7% |
| Return on equity | −45.8% | −54.4% |
| Return on assets | −25.1% | −26.7% |
| Return on tangible equity | −45.8% | −55.2% |
| Growth | ||
| Share count change | — | 7.7% |
| Financial health | ||
| Interest coverage | — | −107.9x |
| Current ratio | 0.3x | 0.6x |
| Quick ratio | 0.1x | 0.1x |
| Quality scores | ||
| Altman Z'' | −3.6 | −4.2 |
| Accruals ratio | −25.2% | −20.8% |
Source: SEC EDGAR XBRL filings (CIK 0001851484). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.